Barclays PLC Kiniksa Pharmaceuticals, Ltd. Call Options Transaction History
Barclays PLC
- $327 Billion
- Q2 2024
Call Options
2 transactions
Others Institutions Holding KNSA
# of Institutions
10Shares Held
1.99MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$32.6 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$4.35 Million2.82% of portfolio
-
Harbor Capital Advisors, Inc.97.5KShares$2.1 Million0.11% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$848,1590.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$644,4000.56% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $740M
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...